期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 11, 期 1, 页码 10-11出版社
NATURE PORTFOLIO
DOI: 10.1038/nrclinonc.2013.231
关键词
-
类别
The international phase III REGARD study demonstrated improved overall survival with ramucirumab as second-line therapy for patients with advanced-stage gastric and gastroesophageal junction adenocarcinoma. As a novel biological treatment, is ramucirumab also the harbinger of a new era of targeted therapies in this prevalent and highly morbid disease?
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据